Inhibition by imatinib of expression of O-glycan-related glycosyltransferases and tumor-associated carbohydrate antigens in the K562 human leukemia cell line

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 4, 2013, Pages 2447-2451

  Sun, Qi Chang ^a   Liu, Mi Bo ^a   Shen, Hong Jie ^b   Jiang, Zhi ^a   Xu, Lan ^a   Gao, Li Ping ^a   Ni, Jian Long ^a   Wu, Shi Liang ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Glycosyltransferases; Imatinib; K562; Leukemia cells; Tumor associated carbohydrate antigens

Indexed keywords

EID: 84930484298     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.4.2447     Document Type: Article

References (20)

1. Boggon TJ, Eck MJ (2004). Structure and regulation of Src family kinases. Oncogene, 23, 7918-27.
2. Brockhausen I (2006). Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep, 7, 599-604.
3. Brockhausen I, Dowler T, Paulsen H (2009). Site directed processing: Role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2. Biochim Biophysica Acta, 1790, 1244-57.
4. Buchdunger E, Zimmermann J, Mett H, et al (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res, 56, 100 4.
5. Danhauser-Riedl S, Warmuth M, Druker BJ, et al (1996). Activation of Src kinases p53/56lyn and p59hck by p210bcr/ abl in myeloid cells. Cancer Res, 56, 3589-96.
6. Deininger MWN, Goldman JM, Lydon N, Melo JV (1997). The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCRABL- positive cells. Blood, 90, 3691 8.
7. Faderl S, Talpaz M, Estrov Z, Kantarjian HM (1999). Chronic myelogenous leukemia: biology and therapygh. Ann Int Med, 131, 207 19.
8. Gerken TA, Owens CL, Pasumarthy M (1998). Site-specific core 1 O-glycosylation pattern of the porcine submaxillary gland mucin tandem repeat Evidence for the modulation of glycan length by peptide sequence. J Biol Chem, 273, 26580-8.
9. Gill DJ, Chia J, Senewiratne J, et al (2010). Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. J Cell Biol, 189, 843-58.
10. Hakomori S (1985). Aberrant glycosylation in cell membranes as focused on glycolipids:overview and perspectives. Cancer Res, 45, 2405-14.
11. Hakomori S (1996). Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res, 56, 5309-18.
12. Heimburg-Molinaro J, Lum M, Vijay G, et al (2011). Cancer vaccines and carbohydrate epitopes. Vaccine, 29, 8802-26.
13. Hitomi T, Seiichi T, Michiie S, et al (2003). Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion. Glycobiology, 13, 521-7
14. Lionberger JM, Wilson MB, Smithgall TE (2000). Transformation of myeloid leukemia cells to cytokine independence by Bcr- Abl is suppressed by kinase-defective Hck. J Biol Chem, 275, 18581-5.
15. Liu C, Lin D, Xu L, et al (2011). An anti-human ppGalNAcT-2 monoclonal antibody. Hybridoma, 30, 549-54.
16. Lozzio CB, Lozzio BB (1975). Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome, Blood, 45, 321-34.
17. Quint s-Cardama A, Cortes J (2009). Molecular biology of bcr-abl1 positive chronic myeloid leukemia. Blood, 113, 1619-30.
18. Reis CA, Osorio H, Silva L, et al (2010). Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol, 63, 322-9.
19. Warmuth M, Bergmann M, Priess A, et al (1997). The Src family kinase Hck interactswith Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem, 272, 33260-70.
20. Yamada K, Mitsui Y, Kakoi N, et al (2012). One-pot characterization of cancer cells by the analysis of mucintype glycans and glycosaminoglycan. Anal Biochem, 421, 595-606.